Dose-Finding Quantitative <sup>18</sup>F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies
Hatice Güngör(Ovarian Cancer Action), Hani Gabra(Royal Children's Hospital), Emily Pickford(Ovarian Cancer Action), Sabin Carme, Nona Rama(Ovarian Cancer Action), Ademi Santiago-Walker(Johnson & Johnson (United States)), Michele Chen(Ovarian Cancer Action), Azeem Saleem, Edward Curry(Age UK), Elizabeth C. Krachey(Research Triangle Park Foundation), Roshan Agarwal(Imperial College Healthcare NHS Trust), Sarah P. Blagden(Churchill Hospital), Mona El‐Bahrawy(Al-Azhar University), Euan A. Stronach(Age UK), Shannon R. Morris(Research Triangle Park Foundation), Roberto Dina(Imperial College London), Cristian Salinas(Hammersmith Hospital), Sam Madison(Research Triangle Park Foundation), Deborah A. Smith(Research Triangle Park Foundation)
Cited by 27
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222